These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

708 related articles for article (PubMed ID: 18317067)

  • 41. Preliminary analysis of a phase II study of paclitaxel, carboplatin, and hyperfractionated radiation therapy for locally advanced inoperable non-small cell lung cancer.
    Choy H; DeVore RF; Hande KR; Porter LL; Rosenblatt P; Yunus F; Schlabach L; Smith C; Shyr Y; LaPorte K; Johnson DH
    Semin Oncol; 1997 Aug; 24(4 Suppl 12):S12-21-S12-26. PubMed ID: 9331115
    [TBL] [Abstract][Full Text] [Related]  

  • 42. How to improve loco-regional control in stages IIIa-b NSCLC? Results of a three-armed randomized trial from the Swedish Lung Cancer Study Group.
    Nyman J; Friesland S; Hallqvist A; Seke M; Bergström S; Thaning L; Lödén B; Sederholm C; Wagenius G
    Lung Cancer; 2009 Jul; 65(1):62-7. PubMed ID: 19081652
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Outcomes treating stage III non-small cell lung carcinoma with curative-intent radiotherapy and concurrent carboplatin-paclitaxel chemotherapy.
    Trinh H; Pinkham MB; Lehman M; Zarate D; Dauth M; McGrath M; McCaffrey E; Mai GT; Horwood K
    Clin Respir J; 2016 Jul; 10(4):428-34. PubMed ID: 25353367
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Incorporating bevacizumab and erlotinib in the combined-modality treatment of stage III non-small-cell lung cancer: results of a phase I/II trial.
    Socinski MA; Stinchcombe TE; Moore DT; Gettinger SN; Decker RH; Petty WJ; Blackstock AW; Schwartz G; Lankford S; Khandani A; Morris DE
    J Clin Oncol; 2012 Nov; 30(32):3953-9. PubMed ID: 23045594
    [TBL] [Abstract][Full Text] [Related]  

  • 45. A phase II study of cisplatin and irinotecan as induction chemotherapy followed by concomitant thoracic radiotherapy with weekly low-dose irinotecan in unresectable, stage III, non-small cell lung cancer: JCOG 9706.
    Takeda K; Negoro S; Tanaka M; Fukuda H; Nakagawa K; Kawahara M; Semba H; Kudoh S; Sawa T; Saijo N; Fukuoka M
    Jpn J Clin Oncol; 2011 Jan; 41(1):25-31. PubMed ID: 20802006
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Phase II trial of combined modality therapy with concurrent topotecan plus radiotherapy followed by consolidation chemotherapy for unresectable stage III and selected stage IV non-small-lung cancer.
    Seung SK; Ross HJ
    Int J Radiat Oncol Biol Phys; 2009 Mar; 73(3):802-9. PubMed ID: 18762390
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Pilot trial of the epidermal growth factor receptor tyrosine kinase inhibitor gefitinib plus carboplatin and paclitaxel in patients with stage IIIB or IV non-small-cell lung cancer.
    Miller VA; Johnson DH; Krug LM; Pizzo B; Tyson L; Perez W; Krozely P; Sandler A; Carbone D; Heelan RT; Kris MG; Smith R; Ochs J
    J Clin Oncol; 2003 Jun; 21(11):2094-100. PubMed ID: 12775734
    [TBL] [Abstract][Full Text] [Related]  

  • 48. A prospective phase II study of induction carboplatin and vinorelbine followed by concomitant topotecan and accelerated radiotherapy (ART) in locally advanced non-small cell lung cancer (NSCLC).
    Patel SH; Ajlouni M; Chapman R; Lu M; Movsas B; Kim JH
    J Thorac Oncol; 2007 Sep; 2(9):831-7. PubMed ID: 17805061
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Induction chemotherapy with carboplatin-paclitaxel followed by standard radiotherapy with concurrent daily low-dose cisplatin plus weekly paclitaxel for inoperable non-small-cell lung cancer.
    Ardizzoni A; Scolaro T; Mereu C; Cafferata MA; Tixi L; Bacigalupo A; Tiseo M; Monetti F; Rosso R
    Am J Clin Oncol; 2005 Feb; 28(1):58-64. PubMed ID: 15685036
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Phase II study of radiotherapy with three-dimensional conformal boost concurrent with paclitaxel and cisplatin for Stage IIIB non-small-cell lung cancer.
    Kim YS; Yoon SM; Choi EK; Yi BY; Kim JH; Ahn SD; Lee SW; Shin SS; Lee JS; Suh C; Kim SW; Kim DS; Kim WS; Park HJ; Park CI
    Int J Radiat Oncol Biol Phys; 2005 May; 62(1):76-81. PubMed ID: 15850905
    [TBL] [Abstract][Full Text] [Related]  

  • 51. nab-Paclitaxel in Combination With Weekly Carboplatin With Concurrent Radiotherapy in Stage III Non-Small Cell Lung Cancer.
    Lammers PE; Lu B; Horn L; Shyr Y; Keedy V
    Oncologist; 2015 May; 20(5):491-2. PubMed ID: 25845992
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Simultaneous chemoradiotherapy compared with radiotherapy alone after induction chemotherapy in inoperable stage IIIA or IIIB non-small-cell lung cancer: study CTRT99/97 by the Bronchial Carcinoma Therapy Group.
    Huber RM; Flentje M; Schmidt M; Pöllinger B; Gosse H; Willner J; Ulm K;
    J Clin Oncol; 2006 Sep; 24(27):4397-404. PubMed ID: 16983107
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Late complications of high-dose (>/=66 Gy) thoracic conformal radiation therapy in combined modality trials in unresectable stage III non-small cell lung cancer.
    Lee CB; Stinchcombe TE; Moore DT; Morris DE; Hayes DN; Halle J; Rosenman JG; Rivera MP; Socinski MA
    J Thorac Oncol; 2009 Jan; 4(1):74-9. PubMed ID: 19096310
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Combined chemoradiotherapy regimens of paclitaxel and carboplatin for locally advanced non-small-cell lung cancer: a randomized phase II locally advanced multi-modality protocol.
    Belani CP; Choy H; Bonomi P; Scott C; Travis P; Haluschak J; Curran WJ
    J Clin Oncol; 2005 Sep; 23(25):5883-91. PubMed ID: 16087941
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Phase I clinical trial of weekly paclitaxel, weekly carboplatin, and concurrent radiotherapy for primary cervical cancer.
    Rao GG; Rogers P; Drake RD; Nguyen P; Coleman RL
    Gynecol Oncol; 2005 Jan; 96(1):168-72. PubMed ID: 15589596
    [TBL] [Abstract][Full Text] [Related]  

  • 56. High-dose accelerated hypofractionated three-dimensional conformal radiotherapy (at 3 Gy/fraction) with concurrent vinorelbine and carboplatin chemotherapy in locally advanced non-small-cell lung cancer: a feasibility study.
    Liu YE; Lin Q; Meng FJ; Chen XJ; Ren XC; Cao B; Wang N; Zong J; Peng Y; Ku YJ; Chen Y
    Radiat Oncol; 2013 Aug; 8(1):198. PubMed ID: 23937855
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Daily paclitaxel and thoracic radiation therapy for non-small cell lung cancer: preliminary results.
    Rathmann J; Leopold KA; Rigas JR
    Semin Radiat Oncol; 1999 Apr; 9(2 Suppl 1):130-5. PubMed ID: 10210552
    [TBL] [Abstract][Full Text] [Related]  

  • 58. A phase II study of cisplatin and irinotecan as induction chemotherapy followed by accelerated hyperfractionated thoracic radiotherapy with daily low-dose carboplatin in unresectable stage III non-small cell lung cancer: JCOG 9510.
    Fujii T; Kunikane H; Okamoto H; Watanabe K; Kunitoh H; Mori K; Yokoyama A; Fukuda H; Tamura T; Saijo N
    Jpn J Clin Oncol; 2009 Dec; 39(12):784-90. PubMed ID: 19770129
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Long-term results of a phase II trial of induction paclitaxel-carboplatin followed by concurrent radiation therapy and weekly paclitaxel and consolidation paclitaxel-carboplatin in stage III non-small cell lung cancer.
    Casas F; Viñolas N; Ferrer F; Agustí C; Sanchez M; Maria Gimferrer J; Lomeña F; Campayo M; Jeremic B
    J Thorac Oncol; 2011 Jan; 6(1):79-85. PubMed ID: 21150466
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Phase II trial of induction gemcitabine and carboplatin followed by conformal thoracic radiation to 74 Gy with weekly paclitaxel and carboplatin in unresectable stage III non-small cell lung cancer.
    Bepler G; Dilling TJ; Wagner H; Hazelton T; Williams C; Chen DT; Greenberg H; Walsh F; Simon G; Tanvetyanon T; Chiappori A; Haura E; Stevens C
    J Thorac Oncol; 2011 Mar; 6(3):553-8. PubMed ID: 21289520
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 36.